Zkusit zdarma
Tyra Biosciences, Inc.

Tyra Biosciences, Inc.

TYRA
Cena:
$ 32.47
-0.55 (-1.67%)
Valuace
70
Růst
0
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

8:00 21-05-2026

-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients li...

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

14:41 17-05-2026

Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary te...

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

17:20 13-05-2026

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcri...

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

8:00 13-05-2026

- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC...

Tyra Biosciences to Participate in Upcoming Investor Conferences

Tyra Biosciences to Participate in Upcoming Investor Conferences

16:05 07-05-2026

CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stag...

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of “Moderate Buy” by Analysts

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of “Moderate Buy” by Analysts

2:22 27-04-2026

Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been assigned an average reco...

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

8:00 17-04-2026

-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's ...

Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock

Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock

4:29 28-03-2026

Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) Director Gilla Kaplan sold 14,295 shares of ...

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

12:01 20-03-2026

Boone Capital added 398,482 shares of TYRA in the fourth quarter. The quarter-end position value ros...

Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

17:30 23-02-2026

CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-st...

Tyra Biosciences to Participate in Upcoming Investor Conferences

Tyra Biosciences to Participate in Upcoming Investor Conferences

16:05 19-02-2026

CARLSBAD, Calif., Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-s...

Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally

Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally

13:27 23-12-2025

Robert More reported the sale of 246,871 shares on Nov. 21 as part of a Rule 10b5-1 trading plan. Th...

Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of “Moderate Buy” from Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of “Moderate Buy” from Brokerages

1:12 23-12-2025

Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been assigned an average reco...

Tyra Biosciences (NASDAQ:TYRA) Hits New 1-Year High – Here’s Why

Tyra Biosciences (NASDAQ:TYRA) Hits New 1-Year High – Here’s Why

3:32 21-12-2025

Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) hit a new 52-week high during trading on Fri...

Tyra Biosciences Announces Participation at Upcoming Investor Events

Tyra Biosciences Announces Participation at Upcoming Investor Events

16:05 12-11-2025

CARLSBAD, Calif. , Nov. 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-s...

Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights

Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights

16:05 05-11-2025

- Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies ...

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

1:31 03-11-2025

Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have received an average rating of...

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

8:00 21-08-2025

-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia-...

Tyra Biosciences Announces Participation at Upcoming Investor Events

Tyra Biosciences Announces Participation at Upcoming Investor Events

16:05 20-08-2025

CARLSBAD, Calif. , Aug. 20, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-s...

Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?

Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?

10:56 19-08-2025

The average of price targets set by Wall Street analysts indicates a potential upside of 178.8% in T...

close

TYRA BIOSCIENCES STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENTS OF BHAVESH ASHAR AS CHIEF OPERATING OFFICER AND HEATHER FAULDS AS CHIEF REGULATORY OFFICER

01-12-2025
CARLSBAD, CALIF. , DEC. 1, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-ST...
Více zde

TYRA BIOSCIENCES ANNOUNCES PARTICIPATION AT UPCOMING INVESTOR EVENTS

12-11-2025
CARLSBAD, CALIF. , NOV. 12, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-S...
Více zde

TYRA BIOSCIENCES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS

05-11-2025
- DOSED FIRST PATIENTS WITH DABOGRATINIB IN BEACH301 AND SURF302; INTERIM RESULTS FROM BOTH STUDIES ...
Více zde

TYRA BIOSCIENCES ANNOUNCES FIRST CHILD DOSED IN BEACH301, ITS PHASE 2 STUDY FOR DABOGRATINIB (TYRA-300) IN PEDIATRIC ACHONDROPLASIA

21-08-2025
-DABOGRATINIB IS THE ONLY ORAL FGFR3-SELECTIVE INHIBITOR IN CLINICAL DEVELOPMENT FOR ACHONDROPLASIA-...
Více zde

TYRA BIOSCIENCES ANNOUNCES PARTICIPATION AT UPCOMING INVESTOR EVENTS

20-08-2025
CARLSBAD, CALIF. , AUG. 20, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-S...
Více zde

TYRA BIOSCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS

14-08-2025
- DOSED FIRST PATIENT IN SURF302 FOR INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (IR NMIBC)...
Více zde

TYRA BIOSCIENCES ANNOUNCES FIRESIDE CHAT ON ACHONDROPLASIA AND GROWTH DISORDERS AT UBS BIOTECH MANAGEMENT LIVE CALL SERIES

21-07-2025
CARLSBAD, CALIF. , JULY 21, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-...
Více zde

TYRA BIOSCIENCES ANNOUNCES LATE-BREAKING POSTER PRESENTATION ON TYRA-300 PRECLINICAL RESULTS AT ENDO 2025

08-07-2025
CARLSBAD, CALIF. , JULY 8, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-...
Více zde

TYRA BIOSCIENCES DOSES FIRST PATIENT IN PHASE 2 STUDY OF TYRA-300 IN LOW-GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (SURF302)

30-06-2025
-TYRA-300 IS THE ONLY ORALLY ADMINISTERED INVESTIGATIONAL AGENT IN CLINICAL DEVELOPMENT FOR IR NMIBC...
Více zde

TYRA BIOSCIENCES TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

12-05-2025
CARLSBAD, CALIF. , MAY 12, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-ST...
Více zde

TYRA BIOSCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS

08-05-2025
- BEACH301 STUDY OF TYRA-300 FOR PEDIATRIC ACHONDROPLASIA (ACH) OPEN FOR ENROLLMENT - - INITIATED PA...
Více zde

TYRA BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND HIGHLIGHTS

27-03-2025
- THREE INDS CLEARED BY US FDA FOR TYRA'S PROPRIETARY PRECISION SMALL MOLECULES - - TYRA-300 TO BE E...
Více zde

TYRA BIOSCIENCES TO PRESENT AT UPCOMING INVESTOR CONFERENCES

11-02-2025
CARLSBAD, CALIF. , FEB. 11, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-S...
Více zde

TYRA BIOSCIENCES ANNOUNCES POSTER PRESENTATIONS AT 2025 ASCO GASTROINTESTINAL CANCERS SYMPOSIUM

22-01-2025
CARLSBAD, CALIF. , JAN. 22, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-S...
Více zde

TYRA BIOSCIENCES RECEIVES IND CLEARANCE FROM FDA TO PROCEED WITH PHASE 2 STUDY OF TYRA-300 IN NON-MUSCLE INVASIVE BLADDER CANCER (SURF302)

10-01-2025
-TYRA APPOINTS UROLOGIC ONCOLOGIST, ERIK GOLUBOFF, M.D., AS SVP, CLINICAL DEVELOPMENT TO LEAD NMIBC-...
Více zde

TYRA BIOSCIENCES TO PRESENT AT UPCOMING INVESTOR CONFERENCES

13-11-2024
CARLSBAD, CALIF. , NOV. 13, 2024 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-...
Více zde

TYRA BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS

07-11-2024
- REPORTED POSITIVE INTERIM CLINICAL PROOF-OF-CONCEPT RESULTS FOR TYRA-300 IN MUC FROM SURF301 PH1/2...
Více zde

TYRA BIOSCIENCES RECEIVES IND CLEARANCE FROM FDA TO PROCEED WITH PHASE 2 STUDY OF TYRA-300 IN PEDIATRIC ACHONDROPLASIA (BEACH301)

28-10-2024
– TYRA-300 IS THE FIRST ORAL FGFR-3 SELECTIVE INHIBITOR TO BE WELL-TOLERATED IN CLINICAL STUDIES ...
Více zde

TYRA BIOSCIENCES REPORTS INTERIM CLINICAL PROOF-OF-CONCEPT DATA FOR TYRA-300, AN INVESTIGATIONAL ORAL FGFR3-SELECTIVE INHIBITOR, IN PHASE 1/2 SURF301 STUDY IN PATIENTS WITH METASTATIC UROTHELIAL CANCER (MUC)

24-10-2024
- ENCOURAGING PRELIMINARY ANTI-TUMOR ACTIVITY OBSERVED IN HEAVILY PRE-TREATED POPULATION - - AT ≥ ...
Více zde

TYRA BIOSCIENCES TO HOST CONFERENCE CALL ON INTERIM CLINICAL DATA OF TYRA-300 FROM SURF301 PHASE 1/2 STUDY ON OCTOBER 25, 2024, AT 8AM ET

23-10-2024
CARLSBAD, CALIF. , OCT. 23, 2024 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-S...
Více zde

TYRA BIOSCIENCES ANNOUNCES LATE-BREAKING ORAL PRESENTATION ON PRELIMINARY SAFETY AND ANTI-TUMOR ACTIVITY OF TYRA-300 FROM SURF301 AT THE 36TH EORTC-NCI-AACR SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS (ENA 2024)

11-10-2024
-TYRA WILL ALSO PRESENT TWO POSTERS ON PK/PD OF TYRA-300 AND A TRIALS-IN-PROGRESS FROM SURF301 - CAR...
Více zde

THE SCHALL LAW FIRM IS LOOKING INTO TYRA BIOSCIENCES INC FOR POSSIBLY VIOLATING SECURITIES LAWS AND THE FIRM SEEKS SHAREHOLDER PARTICIPATION

12-09-2024
LOS ANGELES, CA / ACCESSWIRE / SEPTEMBER 12, 2024 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGH...
Více zde

TYRA BIOSCIENCES TO PRESENT AT THE 2024 CANTOR GLOBAL HEALTHCARE CONFERENCE

11-09-2024
CARLSBAD, CALIF. , SEPT. 11, 2024 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL...
Více zde

TYRA BIOSCIENCES, INC. MAY HAVE DEFRAUDED SHAREHOLDERS AND IMPACTED INDIVIDUALS ARE INVITED TO JOIN THE SCHALL LAW FIRM'S INVESTIGATION

11-09-2024
LOS ANGELES, CA / ACCESSWIRE / SEPTEMBER 11, 2024 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGH...
Více zde

TYRA BIOSCIENCES APPOINTS DOUG WARNER, M.D., AS CHIEF MEDICAL OFFICER

10-09-2024
-DR. WARNER BRINGS OVER TWENTY YEARS OF PROVEN CLINICAL DEVELOPMENT LEADERSHIP TO TYRA HAVING SUCCES...
Více zde

THE SCHALL LAW FIRM HAS LAUNCHED AN INQUIRY INTO TYRA BIOSCIENCES INC FOR SECURITIES LAW VIOLATIONS AND INVESTORS ARE URGED TO CONTRIBUTE

10-09-2024
LOS ANGELES, CA / ACCESSWIRE / SEPTEMBER 10, 2024 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGH...
Více zde

TYRA BIOSCIENCES, INC. IS BEING INVESTIGATED FOR POSSIBLE SECURITIES FRAUD AND THE SCHALL LAW FIRM WANTS SHAREHOLDERS TO PARTICIPATE

09-09-2024
LOS ANGELES, CA / ACCESSWIRE / SEPTEMBER 9, 2024 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHT...
Více zde

FRAUDULENT PRACTICES MAY HAVE BEEN COMMITTED BY TYRA BIOSCIENCES INC AND AFFECTED INVESTORS ARE URGED TO REACH OUT TO THE SCHALL LAW FIRM

07-09-2024
LOS ANGELES, CA / ACCESSWIRE / SEPTEMBER 7, 2024 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHT...
Více zde

INVESTORS ARE INVITED BY THE SCHALL LAW FIRM TO PARTAKE IN AN INQUIRY IN TYRA BIOSCIENCES, INC'S POSSIBLE VIOLATIONS OF SECURITIES REGULATIONS

06-09-2024
LOS ANGELES, CA / ACCESSWIRE / SEPTEMBER 6, 2024 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHT...
Více zde

TYRA BIOSCIENCES, INC. IS BEING LOOKED INTO FOR ACTING WRONGFULLY AND THE SCHALL LAW FIRM HAS LAUNCHED AN INVESTIGATION THAT SHAREHOLDERS CAN JOIN

05-09-2024
LOS ANGELES, CA / ACCESSWIRE / SEPTEMBER 5, 2024 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHT...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2025-12-01 00:00:008-KStáhnout
2025-11-05 00:00:008-KStáhnout
2025-11-05 00:00:0010-QStáhnout
2025-08-22 01:00:008-KStáhnout
2025-08-22 00:00:008-KStáhnout
2025-08-14 01:00:008-KStáhnout
2025-08-14 01:00:0010-QStáhnout
2025-08-14 00:00:008-KStáhnout
2025-08-14 00:00:0010-QStáhnout
2025-06-30 01:00:008-KStáhnout
2025-06-30 00:00:008-KStáhnout
2025-05-29 01:00:008-KStáhnout
2025-05-29 00:00:008-KStáhnout
2025-05-08 01:00:008-KStáhnout
2025-05-08 01:00:0010-QStáhnout
2025-05-08 00:00:008-KStáhnout
2025-05-08 00:00:0010-QStáhnout
2025-03-27 00:00:008-KStáhnout
2025-03-27 00:00:0010-KStáhnout
2025-03-26 23:00:008-KStáhnout
2025-03-26 23:00:0010-KStáhnout
2025-01-29 00:00:008-KStáhnout
2025-01-28 23:00:008-KStáhnout
2024-11-07 00:00:008-KStáhnout
2024-11-07 00:00:0010-QStáhnout
2024-11-06 23:00:008-KStáhnout
2024-11-06 23:00:0010-QStáhnout
2024-10-28 00:00:008-KStáhnout
2024-10-27 23:00:008-KStáhnout
2024-10-25 01:00:008-KStáhnout
2024-10-25 00:00:008-KStáhnout
2024-10-18 01:00:008-KStáhnout
2024-10-18 00:00:008-KStáhnout
2024-08-07 01:00:008-KStáhnout
2024-08-07 01:00:0010-QStáhnout
2024-08-07 00:00:008-KStáhnout
2024-08-07 00:00:0010-QStáhnout
2024-05-31 01:00:008-KStáhnout
2024-05-31 00:00:008-KStáhnout
2024-05-09 01:00:008-KStáhnout
2024-05-09 01:00:0010-QStáhnout
2024-05-09 00:00:008-KStáhnout
2024-05-09 00:00:0010-QStáhnout
2024-05-07 01:00:008-KStáhnout
2024-05-07 00:00:008-KStáhnout
2024-03-19 00:00:008-KStáhnout
2024-03-19 00:00:0010-KStáhnout
2024-03-18 23:00:008-KStáhnout
2024-03-18 23:00:0010-KStáhnout
2024-02-05 00:00:008-KStáhnout
2024-02-04 23:00:008-KStáhnout
2024-02-01 00:00:008-KStáhnout
2024-01-31 23:00:008-KStáhnout
2023-12-22 00:00:008-KStáhnout
2023-12-21 23:00:008-KStáhnout
2023-11-07 00:00:008-KStáhnout
2023-11-07 00:00:0010-QStáhnout
2023-11-06 23:00:008-KStáhnout
2023-11-06 23:00:0010-QStáhnout
2023-10-26 01:00:008-KStáhnout
2023-10-26 00:00:008-KStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 01:00:0010-QStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-10 00:00:0010-QStáhnout
2023-06-02 01:00:008-KStáhnout
2023-06-02 00:00:008-KStáhnout
2023-05-04 01:00:008-KStáhnout
2023-05-04 01:00:0010-QStáhnout
2023-05-04 00:00:008-KStáhnout
2023-05-04 00:00:0010-QStáhnout
2023-03-22 00:00:008-KStáhnout
2023-03-22 00:00:0010-KStáhnout
2023-03-21 23:00:008-KStáhnout
2023-03-21 23:00:0010-KStáhnout
2023-03-01 00:00:008-KStáhnout
2023-02-28 23:00:008-KStáhnout
2022-11-29 00:00:008-KStáhnout
2022-11-28 23:00:008-KStáhnout
2022-11-03 00:00:008-KStáhnout
2022-11-03 00:00:0010-QStáhnout
2022-11-02 23:00:008-KStáhnout
2022-11-02 23:00:0010-QStáhnout
2022-10-03 01:00:008-KStáhnout
2022-10-03 00:00:008-KStáhnout
2022-08-04 01:00:008-KStáhnout
2022-08-04 01:00:0010-QStáhnout
2022-08-04 00:00:008-KStáhnout
2022-08-04 00:00:0010-QStáhnout
2022-06-14 01:00:008-KStáhnout
2022-06-14 00:00:008-KStáhnout
2022-05-05 01:00:008-KStáhnout
2022-05-05 01:00:0010-QStáhnout
2022-05-05 00:00:008-KStáhnout
2022-05-05 00:00:0010-QStáhnout
2022-03-03 00:00:008-KStáhnout
2022-03-03 00:00:0010-KStáhnout
2022-03-02 23:00:008-KStáhnout
2022-03-02 23:00:0010-KStáhnout
2021-11-03 00:00:008-KStáhnout
2021-11-03 00:00:0010-QStáhnout
2021-11-02 23:00:008-KStáhnout
2021-11-02 23:00:0010-QStáhnout
2021-09-17 01:00:008-KStáhnout
2021-09-17 00:00:008-KStáhnout
preloader